Earnings Releases·Oct 27, 2026, 4:30 PM ET

Chemed Corporation — Third Quarter 2026 Earnings Summary

Consolidated revenue rose 10.6% year-over-year to $690.9 million, driven by a 22.2% increase in GAAP diluted EPS to $5.45 and a 28.1% rise in adjusted diluted EPS to $6.75.
VITAS segment performance was robust with 12.2% revenue growth to $457.4 million and 31.4% adjusted EBITDA growth to $92.5 million, while Roto-Rooter saw 7.5% revenue growth to $233.5 million despite a 2.5% decline in adjusted EBITDA to $48.2 million.
Full-year 2026 adjusted EPS guidance is estimated to be at or slightly above the high-end of the July 2026 forecast, reflecting strong volume and reimbursement rate growth in VITAS.
Strategic capital allocation included the re-acquisition of multiple California franchise territories for approximately $62.5 million and the repurchase of 125,000 shares for $66.0 million during the quarter.
The company maintains a $450 million credit facility with $166.7 million in undrawn borrowing capacity and ended the quarter with $48.4 million in cash and $236.0 million in long-term debt.